Dermatology News and Research

Latest Dermatology News and Research

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Sucampo Pharmaceuticals, Inc. today confirmed that its partner, R-Tech Ueno, Ltd. reported the results of its recently completed phase 2 clinical trial of UF-021 in retinitis pigmentosa patients. The results showed improvement in visual function dose-dependently in both visual field test and subjective findings.

5 Jun 2010

R-Tech Ueno announces completion of Phase II clinical study of UF-021 for retinitis pigmentosa

We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva, which we are developing as a therapeutic drug for retinitis pigmentosa, has been completed.

4 Jun 2010

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London on June 7th. The results will be presented by the study's principal investigator Prof. Eric Bateman.

4 Jun 2010

Researchers describe chain of molecular events that increase one's risk of skin cancer

As people head to the beach this summer, very few if any, really know how likely they are to develop skin cancer from their outdoor fun. That's about to change, thanks to a new discovery by an international team of scientists that makes it possible for doctors to access people's personal risk for skin cancer.

3 Jun 2010

Incidence of skin cancer cases increases particularly among teenagers

With the family beach vacation right around the corner, keeping children's skin safe under the hot, summer sun should be top of mind for every parent. Recently, doctors at Nationwide Children's Hospital have seen an increase in the incidence of skin cancer cases among children ages 5-16-years-old, and particularly among teenagers. In fact, melanoma - cancer of the skin's pigment elements - is now responsible for approximately one out of 10 cancer cases in adolescents ages 15-19-years-old.

3 Jun 2010

Oculus launches Microcyn Negative-Pressure Wound Therapy Solution

Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today introduced the Microcyn Negative-Pressure Wound Therapy Solution™ for the U.S. professional healthcare market. Within the pH ranges of 6-7.8 desired for optimum negative-pressure wound therapy, Microcyn is intended for the irrigation and management of wounds via these advanced systems.

2 Jun 2010

LEO Pharma to find alternative solution to withdraw pharmaceutical products from Greek market

LEO Pharma is in dialogue with the Greek authorities to find an alternative solution to withdrawing the company's pharmaceutical products from the Greek market.

2 Jun 2010

Scientists identify new susceptibility genes in genome-wide association study of nasopharyngeal carcinoma

Scientists from Singapore, China and USA have identified three new susceptibility genes in a genome-wide association study of nasopharyngeal carcinoma (NPC). The study, led by the Genome Institute of Singapore (GIS), a biomedical research institute of the Agency for Science, Technology and Research (A*STAR), and the Sun Yat-Sen University Cancer Centre, identified genetic risk factors of NPC that advance the understanding of the important role played by host genetic variation in influencing the susceptibility to this cancer.

31 May 2010

Allergic reactions prevent people with allergic asthma from generating healthy immune response to influenza

New research from UT Southwestern Medical Center suggests that allergic reactions to pet dander, dust mites and mold may prevent people with allergic asthma from generating a healthy immune response to respiratory viruses such as influenza.

29 May 2010

FDA approves Cysview for detection of non-muscle-invasive papillary cancer of bladder

GE Healthcare, a unit of General Electric Company, today announced that the US Food and Drug Administration has approved Cysview (hexaminolevulinate HCl) for the detection of non-muscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer.

29 May 2010

Simoni Lift minimally invasive surgery to be revealed at international facial cosmetic surgery symposium

Renowned surgeons and aesthetic practitioners from around the world will be gathering to share and discuss the latest techniques and technologies in cosmetic surgery and dermatology at The 6th Annual Facial Cosmetic Surgery International Multi-Specialty Symposium in Las Vegas, July 14-18. For the first time, Beverly Hills Facial Plastic Surgeon Payman Simoni, MD, FACS, will be revealing the highly specialized techniques he has perfected with his highly publicized Simoni Lift™.

28 May 2010

SonoSite signs agreement to acquire privately held Visualsonics

SonoSite, Inc., the world leader and specialist in bedside and point-of-care ultrasound, today announced that it has signed an agreement to acquire privately held Visualsonics, a Toronto-based company focused on ultra high-frequency micro-ultrasound technology. The aggregate transaction value will be approximately $71 million net of cash and debt.

27 May 2010

Report: Use of indoor tanning beds increases risk of melanoma

Use of indoor tanning beds increases risk of melanoma between twofold and fourfold depending on the device and length of time indoor tanning is used, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

27 May 2010

Impax Laboratories, IGI Laboratories announce product development and supply agreement

Impax Laboratories, Inc. today announced that it has entered into a product development and supply agreement with IGI Laboratories, Inc., a formulation and manufacturing company. IGI will be responsible for developing two topical drug products, obtaining FDA marketing approvals, and manufacturing the commercial products.

27 May 2010

Physicians able to retrieve medical evidence from smartphones

Global scientific, technical, medical and scholarly publisher Wiley-Blackwell today announced the that its evidence-based clinical decision support product, Essential Evidence Plus, is now accessible from mobile devices. Physicians on the move can now easily find answers to challenging point-of-care questions from their iPhoneTM, IPod Touch-, AndroidTM, Blackberry- or other Smartphones.

26 May 2010

KCI to feature expanded line of NPTP products and services at EWMA congress

Kinetic Concepts, Inc. today announced the company will feature its expanded line of negative pressure technology platform products and services at the annual European Wound Management Association congress in Geneva, Switzerland. Highlighting the company's commitment to innovative therapies, the new product line will improve the portability and adoption of V.A.C. Therapy, while further specializing the clinical application of negative pressure.

26 May 2010

Valocor Therapeutics acquires, licenses dermatology therapeutic programs from QLT

Valocor Therapeutics, Inc., a newly formed company focused on the development of innovative therapies for the treatment of dermatologic conditions, today announced the acquisition and license of certain dermatology therapeutic programs from QLT Inc.. This transaction was facilitated by a seed financing for Valocor led by the Working Opportunity Fund, which is managed by GrowthWorks Capital Ltd.

25 May 2010

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today announced the completion of enrollment in a Phase 2a proof-of-concept trial for the treatment of impetigo.

25 May 2010

LEO Pharma implements Cegedim Dendrite's Mobile Intelligence CRM solution in 6 Asia-Pacific countries

Cegedim Dendrite today announced that LEO Pharma has implemented Mobile Intelligence™, Cegedim Dendrite's flagship Customer Relationship Management (CRM) solution using a Software as a Service (SaaS) delivery model, in six countries in the Asia-Pacific region. LEO Pharma is a global pharmaceutical company specializing in dermatology and critical care and Cegedim Dendrite is the world's leading provider of Pharmaceutical CRM solutions with a 35 percent global market share.

25 May 2010

Dermatologists recommend broad spectrum sunscreen products to protect against UVA and UVB rays

Sunscreen active ingredients, which are compounds that absorb, scatter or reflect ultraviolet (UV) light, are regulated as over-the-counter (OTC) drugs by the U.S. Food and Drug Administration (FDA).

25 May 2010

Dermatology News and Research

Latest Dermatology News and Research

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

R-Tech Ueno announces completion of Phase II clinical study of UF-021 for retinitis pigmentosa

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Researchers describe chain of molecular events that increase one's risk of skin cancer

Incidence of skin cancer cases increases particularly among teenagers

Oculus launches Microcyn Negative-Pressure Wound Therapy Solution

LEO Pharma to find alternative solution to withdraw pharmaceutical products from Greek market

Scientists identify new susceptibility genes in genome-wide association study of nasopharyngeal carcinoma

Allergic reactions prevent people with allergic asthma from generating healthy immune response to influenza

FDA approves Cysview for detection of non-muscle-invasive papillary cancer of bladder

Simoni Lift minimally invasive surgery to be revealed at international facial cosmetic surgery symposium

SonoSite signs agreement to acquire privately held Visualsonics

Report: Use of indoor tanning beds increases risk of melanoma

Impax Laboratories, IGI Laboratories announce product development and supply agreement

Physicians able to retrieve medical evidence from smartphones

KCI to feature expanded line of NPTP products and services at EWMA congress

Valocor Therapeutics acquires, licenses dermatology therapeutic programs from QLT

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

LEO Pharma implements Cegedim Dendrite's Mobile Intelligence CRM solution in 6 Asia-Pacific countries

Dermatologists recommend broad spectrum sunscreen products to protect against UVA and UVB rays

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dermatology News and Research

Latest Dermatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in